Shots:
Innovent has reported the P-III (G-HOPE-001) of arcotatug tavatecan (IBI343/TAK-921) vs investigator-selected therapy in pts with Claudin 18.2 positive, locally advanced unresectable or metastatic G/GEJA who have received ≥2 prior therapies
Trial met its 1EP of improved PFS in the interim analysis & showed a favorable safety profile; data to be published in future…
